Healthcare · Pharmaceuticals & Biotechnology
QVM read Cheap on its own multiples Quality Moderate, Valuation Undervalued, Momentum Neutral
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Ranks #164 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 12 Aug 2026 | GOKULAM FARMS | Bulk | Buy | 13,701 | 81.4700 | BSE |
| 9 Jul 2026 | DIVYA KANDA | Bulk | Buy | 39,500 | 63.5600 | BSE |
| 1 Jul 2026 | BIJAL KISHORCHANDRA MADHANI | Bulk | Buy | 15,000 | 87.2400 | BSE |
| 30 Jan 2026 | BONANZA PORTFOLIO LIMITED | Bulk | Buy | 7,000 | 86.9400 | BSE |
| 30 Jan 2026 | BONANZA PORTFOLIO LIMITED | Bulk | Sell | 14,260 | 78.3000 | BSE |
| 30 Jan 2026 | F3 ADVISORS PRIVATE LIMITED | Bulk | Buy | 14,741 | 79.6800 | BSE |
| 30 Jan 2026 | F3 ADVISORS PRIVATE LIMITED | Bulk | Sell | 14,741 | 85.9400 | BSE |
| 30 Jan 2026 | GAURAV AGARWAL | Bulk | Buy | 16,338 | 84.4600 | BSE |
| 9 May 2025 | KEYUR SURESHBHAI SHAH | Bulk | Buy | 13,702 | 53.9900 | BSE |
| 10 Jul 2024 | BHUPESH GUPTA | Bulk | Buy | 12,731 | 80.9800 | BSE |
Exchange disclosures (NSE and BSE), most recent first.
| Date | Category | Announcement |
|---|---|---|
| 1 Oct 2026 | Company Update | Colinz Laboratories Ltd - 531210 - Declaration Of Non-Applicability Of Reg. 32 Of The SEBI (LODR) Regulations, 2015 (Statement Of Deviation Or Variation For Proceeds Of Public Issue, Rights Issue, Preferential Issue, QIP) For The Quarter Ended 30.09.2026. |
| 1 Oct 2026 | Company Update | Colinz Laboratories Ltd - 531210 - Declaration With Respect To Non-Applicability Of Related Party Transactions Pursuant To Regulations 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements, Regulation 2015). |
| 29 Sep 2026 | Insider Trading / SAST | Colinz Laboratories Ltd - 531210 - Closure of Trading Window |
| 4 Sep 2026 | Company Update | Colinz Laboratories Ltd - 531210 - Post Offer Advertisement |
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Board of directors and corporate information →
Data unavailable (no single-stock futures or options activity on record for this company).
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
